{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:14:28Z","timestamp":1780064068978,"version":"3.54.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023326","name":"Britannia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Levodopa\u2013entacapone\u2013carbidopa intestinal gel (LECIG) infusion is a device-aided therapy (DAT) for advanced Parkinson\u2019s disease (APD). ELEGANCE (NCT05043103) is a multinational observational study gathering real-world data on long-term efficacy, safety and patient-reported outcomes with LECIG. Here we report the experience of 69 patients (41%) in the ELEGANCE interim analysis cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009167) from Romanian tertiary centers. The following outcomes were recorded: reduction in daily OFF time and time spent with dyskinesia (based on MDS-UPDRS part IV, questions 4.3 and 4.1, respectively), scores for MDS-UPDRS part II, treatment-emergent adverse events (AEs), non-motor symptoms (NMS), quality of life (QoL), patients\u2019 perceptions of the device and, from visit (V) 2, patient and clinician global impression of improvement (PGI-I and CGI-I). Mean daily OFF time was significantly improved from baseline at V2 (3\u20136 months of treatment) and V3 (6\u201312 months) to &lt;\u20092\u00a0h per day. The most common AE was device dislocation (6 patients, 8.7%). One patient experienced an AE that required treatment withdrawal. There were improvements in scores for NMS Scale domains, notably sleep parameters and gastrointestinal function, and in Parkinson\u2019s Disease Sleep Scale 2. Clinically meaningful improvements in QoL measures were observed. PGI-I and CGI-I scores showed substantial improvement. Patient-reported satisfaction with the pump was high. LECIG treatment for up to one year of APD patients at Romanian centers provided effective control of motor symptoms and was well tolerated, with few discontinuations. Additional benefit was observed on some NMS, in particular sleep, and in QoL.\n                  <\/jats:p>","DOI":"10.1007\/s00702-026-03182-4","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:59:51Z","timestamp":1780063191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Levodopa\u2013entacapone\u2013carbidopa intestinal gel in advanced Parkinson\u2019s disease: an analysis of interim data for Romanian patients enrolled in the ELEGANCE study"],"prefix":"10.1007","author":[{"given":"J\u00f3zsef Attila","family":"Sz\u00e1sz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Vasilica","family":"Blesneag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traian Flavius","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viorelia Adelina","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafin Fior","family":"Mure\u015fanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drago\u015f C\u0103t\u0103lin","family":"Jianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Any","family":"Axelerad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Tulb\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan Ovidiu","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"5","key":"3182_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/nmt-2020-0021","volume":"10","author":"J Aldred","year":"2020","unstructured":"Aldred J, Anca-Herschkovitsch M, Antonini A, Bajenaru O, Bergmann L, Bourgeois P, Cubo E, Davis TL, Iansek R, Kovacs N, Kukreja P, Onuk K, Pontieri FE, Robieson W, Siddiqui MS, Simu M, Standaert DG, Chaudhuri KR (2020) Application of the \u20185-2-1\u2019 screening criteria in advanced Parkinson\u2019s disease: interim analysis of DUOGLOBE. Neurodegener Dis Manag 10(5):309\u2013323. https:\/\/doi.org\/10.2217\/nmt-2020-0021","journal-title":"Neurodegener Dis Manag"},{"issue":"6","key":"3182_CR2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC (2023) Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12(6):1937\u20131958. https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Ther"},{"key":"3182_CR3","first-page":"1","volume":"2","author":"S Berit","year":"2010","unstructured":"Berit S, Nyholm D (2010) Patient-perceived retrospective outcome of duodenal levodopa infusion in advanced Parkinson\u00b4s disease. Eur Neurol J 2:1\u20138","journal-title":"Eur Neurol J"},{"issue":"7","key":"3182_CR4","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4(7):28\u201337","journal-title":"Psychiatry (Edgmont)"},{"issue":"2","key":"3182_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1468-1331.2008.02212.x","volume":"15","author":"KR Chaudhuri","year":"2008","unstructured":"Chaudhuri KR, Martinez-Martin P (2008) Quantitation of non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol 15(2):2\u20137. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02212.x","journal-title":"Eur J Neurol"},{"issue":"13","key":"3182_CR6","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH (2007) The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov Disord 22(13):1901\u20131911. https:\/\/doi.org\/10.1002\/mds.21596","journal-title":"Mov Disord"},{"key":"3182_CR7","unstructured":"Comtan European Public Assessment Report (2008)"},{"issue":"3","key":"3182_CR8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/ene.13844","volume":"26","author":"M Fabbri","year":"2019","unstructured":"Fabbri M, Zibetti M, Beccaria L, Merola A, Romagnolo A, Montanaro E, Ferreira JJ, Palermo S, Lopiano L (2019) Levodopa\/carbidopa intestinal gel infusion and weight loss in Parkinson\u2019s disease. Eur J Neurol 26(3):490\u2013496. https:\/\/doi.org\/10.1111\/ene.13844","journal-title":"Eur J Neurol"},{"issue":"8","key":"3182_CR9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.neurol.2020.11.017","volume":"177","author":"B Fernandez-Rodriguez","year":"2021","unstructured":"Fernandez-Rodriguez B, Dupouy J, Harroch E, Fabre-Delcros MH, Barthelemy C, Loubiere P, Barange K, Brefel-Courbon C, Rascol O, Ory-Magne F (2021) Body mass index variations in patients with Parkinson\u2019s disease treated with levodopa-carbidopa intestinal gel infusion: a case control study versus standard of care and subthalamic nucleus deep brain stimulation. Rev Neurol (Paris) 177(8):919\u2013923. https:\/\/doi.org\/10.1016\/j.neurol.2020.11.017","journal-title":"Rev Neurol (Paris)"},{"issue":"2","key":"3182_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0037-1602423","volume":"37","author":"ME Freitas","year":"2017","unstructured":"Freitas ME, Hess CW, Fox SH (2017) Motor complications of dopaminergic medications in Parkinson\u2019s disease. Semin Neurol 37(2):147\u2013157. https:\/\/doi.org\/10.1055\/s-0037-1602423","journal-title":"Semin Neurol"},{"issue":"6","key":"3182_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/mdc3.14044","volume":"11","author":"SE Gandhi","year":"2024","unstructured":"Gandhi SE, Zerenner T, Nodehi A, Lawton MA, Marshall V, Al-Hajraf F, Grosset KA, Morris HR, Hu MT, Ben-Shlomo Y, Grosset DG (2024) Motor complications in Parkinson\u2019s Disease: results from 3343 patients followed for up to 12 years. Mov Disord Clin Pract 11(6):686\u2013697. https:\/\/doi.org\/10.1002\/mdc3.14044","journal-title":"Mov Disord Clin Pract"},{"issue":"15","key":"3182_CR12","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Disorders 23(15):2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Movement Disorders"},{"key":"3182_CR13","volume-title":"ECDEU Assessment Manual for Psychopharmacology, revised","author":"W Guy","year":"1976","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology, revised. US Government Printing Office, Washington, DC"},{"key":"3182_CR14","doi-asserted-by":"publisher","unstructured":"Horvath K, Aschermann Z, Acs P, Deli G, Janszky J, Komoly S, Karadi K, Kovacs M, Makkos A, Faludi B, Kovacs N (2015a) Minimal Clinically Important Difference on Parkinson\u2019s Disease Sleep Scale 2nd Version. Parkinson\u2019s disease 2015(970534). https:\/\/doi.org\/10.1155\/2015\/970534","DOI":"10.1155\/2015\/970534"},{"key":"3182_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/970534","volume":"2015","author":"K Horvath","year":"2015","unstructured":"Horvath K, Aschermann Z, Acs P, Deli G, Janszky J, Komoly S, Karadi K, Kovacs M, Makkos A, Faludi B, Kovacs N (2015) Minimal clinically important difference on Parkinson\u2019s Disease Sleep Scale 2nd version. Parkinsons Dis 2015:970534. https:\/\/doi.org\/10.1155\/2015\/970534","journal-title":"Parkinsons Dis"},{"issue":"1\u20132","key":"3182_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horvath","year":"2017","unstructured":"Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, Komoly S, Karadi K, Kovacs N (2017a) Changes in quality of life in Parkinson\u2019s Disease: how large must they be to be relevant? Neuroepidemiology 48(1\u20132):1\u20138. https:\/\/doi.org\/10.1159\/000455863","journal-title":"Neuroepidemiology"},{"issue":"5","key":"3182_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horvath","year":"2017","unstructured":"Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, Komoly S, Karadi K, Kovacs N (2017b) Minimal clinically important differences for the experiences of daily living parts of Movement Disorder Society-sponsored Unified Parkinson\u2019s Disease Rating Scale. Movement Disorders 32(5):789\u2013793. https:\/\/doi.org\/10.1002\/mds.26960","journal-title":"Movement Disorders"},{"issue":"5","key":"3182_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horvath","year":"2017","unstructured":"Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, Komoly S, Karadi K, Kovacs N (2017c) Minimal clinically important differences for the experiences of daily living parts of Movement Disorder Society-sponsored Unified Parkinson\u2019s Disease Rating Scale. Mov Disord 32(5):789\u2013793. https:\/\/doi.org\/10.1002\/mds.26960","journal-title":"Mov Disord"},{"issue":"5","key":"3182_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson\u2019s Disease questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing 26(5):353\u2013357","journal-title":"Age Ageing"},{"key":"3182_CR20","doi-asserted-by":"publisher","unstructured":"Jost ST, Aloui S, Evans J, Ashkan K, Sauerbier A, Rizos A, Petry-Schmelzer JN, Gronostay A, Fink GR, Visser-Vandewalle V, Antonini A, Silverdale M, Timmermann L, Martinez-Martin P, Chaudhuri KR, Dafsari HS, International P, Movement Disorders Society Non-Motor Parkinson\u2019s Disease Study G, Europar (2024) Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years: A Nonrandomized Controlled Trial. JAMA Netw Open 7 (1):e2352177. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52177","DOI":"10.1001\/jamanetworkopen.2023.52177"},{"issue":"9","key":"3182_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17(9):749\u2013759. https:\/\/doi.org\/10.1016\/S1474-4422(18)30239-4","journal-title":"Lancet Neurol"},{"key":"3182_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2020.12.024","volume":"83","author":"R Katzenschlager","year":"2021","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Lockhart D, Staines H, Lees A (2021) Long-term safety and efficacy of apomorphine infusion in Parkinson\u2019s disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord 83:79\u201385. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.12.024","journal-title":"Parkinsonism Relat Disord"},{"key":"3182_CR23","unstructured":"LECIGON Summary of Product Characteristics (2022) https:\/\/www.medicines.org.uk\/emc\/product\/14160\/smpc"},{"key":"3182_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13092191","author":"M Lungu","year":"2025","unstructured":"Lungu M, Oprea VD, Apostol LL, Elkan EM, Ionescu AM, Tudor A, Zaharia LA (2025) Levodopa-carbidopa-entacapone intestinal gel for advanced Parkinson\u2019s disease-results from a monocentric study evaluating both motor and non-motor manifestations. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines13092191","journal-title":"Biomedicines"},{"key":"3182_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","volume":"58","author":"A Makkos","year":"2019","unstructured":"Makkos A, Kovacs M, Pinter D, Janszky J, Kovacs N (2019a) Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale. Parkinsonism Relat Disord 58:79\u201382. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.08.018","journal-title":"Parkinsonism Relat Disord"},{"key":"3182_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","volume":"58","author":"A Makkos","year":"2019","unstructured":"Makkos A, Kovacs M, Pinter D, Janszky J, Kovacs N (2019b) Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale. Parkinsonism Relat Disord 58:79\u201382. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.08.018","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"3182_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.14802\/jmd.25042","volume":"18","author":"V Metta","year":"2025","unstructured":"Metta V, Benamer HTS, Kapsas G, Mridula R, Alugolu R, Hussain H, Nalarakettil A, Sai SKN, Elmahdy M, Borgohain R, Chaudhuri KR (2025) MRI-guided focused ultrasound in Parkinson\u2019s disease and essential tremor: incisionless but invasive. A narrative review. J Mov Disord 18(4):289\u2013303. https:\/\/doi.org\/10.14802\/jmd.25042","journal-title":"J Mov Disord"},{"issue":"11","key":"3182_CR28","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/mds.27883","volume":"34","author":"H Morales-Briceno","year":"2019","unstructured":"Morales-Briceno H, Mahant N, Ha AD, Chang FCF, Kim SD, Griffith J, Tsui D, Galea D, Fung VSC (2019) Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson\u2019s disease. Mov Disord 34(11):1747\u20131748. https:\/\/doi.org\/10.1002\/mds.27883","journal-title":"Mov Disord"},{"key":"3182_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221108018","volume":"15","author":"D Nyholm","year":"2022","unstructured":"Nyholm D, Jost WH (2022) Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: real-world experience and practical guidance. Ther Adv Neurol Disord 15:17562864221108018. https:\/\/doi.org\/10.1177\/17562864221108018","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"3182_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, Group LHS (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13(2):141\u2013149. https:\/\/doi.org\/10.1016\/S1474-4422(13)70293-X","journal-title":"Lancet Neurol"},{"key":"3182_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040254","author":"M Othman","year":"2021","unstructured":"Othman M, Widman E, Nygren I, Nyholm D (2021) Initial experience of the levodopa-entacapone-carbidopa intestinal gel in clinical practice. J Pers Med. https:\/\/doi.org\/10.3390\/jpm11040254","journal-title":"J Pers Med"},{"issue":"1","key":"3182_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2023-000705","volume":"3","author":"JJ Petersen","year":"2024","unstructured":"Petersen JJ, Kamp CB, Faltermeier P, Juul S, Lokkegaard A, Gluud C, Jakobsen JC (2024) Deep brain stimulation for Parkinson\u2019s disease: systematic review with meta-analysis and trial sequential analysis. BMJ Med 3(1):e000705. https:\/\/doi.org\/10.1136\/bmjmed-2023-000705","journal-title":"BMJ Med"},{"issue":"Suppl 1","key":"3182_CR33","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1007\/PL00007730","volume":"245","author":"V Peto","year":"1998","unstructured":"Peto V, Jenkinson C, Fitzpatrick R (1998) PDQ-39: a review of the development, validation and application of a Parkinson\u2019s disease quality of life questionnaire and its associated measures. J Neurol 245(Suppl 1):S10-14","journal-title":"J Neurol"},{"issue":"6","key":"3182_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/17434440.2025.2499153","volume":"22","author":"K Poplawska-Domaszewicz","year":"2025","unstructured":"Poplawska-Domaszewicz K, Metta V, Odin P, Chaudhuri KR (2025) The device-aided intrajejunal delivery of levodopa-entacapone-carbidopa intestinal gel the treatment of Parkinson\u2019s disease: overview of efficacy and safety. Expert Rev Med Devices 22(6):533\u2013544. https:\/\/doi.org\/10.1080\/17434440.2025.2499153","journal-title":"Expert Rev Med Devices"},{"key":"3182_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.parkreldis.2019.07.031","volume":"66","author":"D Santos Garcia","year":"2019","unstructured":"Santos Garcia D, de Deus Fonticoba T, Suarez Castro E, Borrue C, Mata M, Solano Vila B, Cots Foraster A, Alvarez Sauco M, Rodriguez Perez AB, Vela L, Macias Y, Escalante S, Esteve P, Reverte Villarroya S, Cubo E, Casas E, Arnaiz S, Carrillo Padilla F, Pueyo Morlans M, Mir P, Martinez-Martin P, Coppadis Study G (2019) Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson\u2019s disease patients: results from the COPPADIS Study Cohort. Parkinsonism Relat Disord 66:151\u2013157. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.031","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"3182_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00256-w","volume":"7","author":"D Santos Garcia","year":"2021","unstructured":"Santos Garcia D, de Deus Fonticoba T, Cores C, Munoz G, Paz Gonzalez JM, Martinez Miro C, Suarez E, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Garcia Caldentey J, Caballol N, Legarda I, Hernandez Vara J, Cabo I, Lopez Manzanares L, Gonzalez Aramburu I, Avila Rivera MA, Catalan MJ, Nogueira V, Puente V, Ruiz de Arcos M, Borrue C, Solano Vila B, Alvarez Sauco M, Vela L, Escalante S, Cubo E, Carrillo Padilla F, Martinez Castrillo JC, Sanchez Alonso P, Alonso Losada MG, Lopez Ariztegui N, Gaston I, Clavero P, Kulisevsky J, Blazquez Estrada M, Seijo M, Ruiz Martinez J, Valero C, Kurtis M, de Fabregues O, Gonzalez Ardura J, Ordas C, Lopez Diaz LM, McAfee D, Martinez-Martin P, Mir P, Group CS (2021) Predictors of clinically significant quality of life impairment in Parkinson\u2019s disease. NPJ Parkinsons Dis 7(1):118. https:\/\/doi.org\/10.1038\/s41531-021-00256-w","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"3182_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","volume":"32","author":"M Senek","year":"2017","unstructured":"Senek M, Nielsen EI, Nyholm D (2017) Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: a randomized crossover study. Mov disorders: official J Mov Disorder Soc 32(2):283\u2013286. https:\/\/doi.org\/10.1002\/mds.26855","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"2","key":"3182_CR38","doi-asserted-by":"publisher","first-page":"208","DOI":"10.14802\/jmd.23172","volume":"17","author":"K Smilowska","year":"2024","unstructured":"Smilowska K, Pietrzykowski T, Chaudhuri KR, Bloem BR, Wamelen DJV (2024) Accessibility of device-aided therapies for persons with Parkinson\u2019s disease in Poland. J Mov Disord 17(2):208\u2013212. https:\/\/doi.org\/10.14802\/jmd.23172","journal-title":"J Mov Disord"},{"issue":"12","key":"3182_CR39","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O\u2019Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou EO, Zheng H, Facheris MF, Hauser RA (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21(12):1099\u20131109. https:\/\/doi.org\/10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"3182_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061115","author":"JA Szasz","year":"2022","unstructured":"Szasz JA, Constantin VA, Orban-Kis K, Bancu LA, Bataga SM, Ciorba M, Nagy E, Neagoe MR, Mihaly I, Szasz RM, Kelemen K, Simu M, Szatmari S (2022) Levodopa-carbidopa intestinal gel in advanced parkinson\u2019s Disease: Observations and Dilemmas after 10 Years of Real-Life Experience. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14061115","journal-title":"Pharmaceutics"},{"key":"3182_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001707","author":"JA Szasz","year":"2024","unstructured":"Szasz JA, Dulamea AO, Constantin VA, Muresanu DF, Dumbrava LP, Tiu C, Jianu DC, Simu M, Ene A, Axelerad A, Falup-Pecurariu C, Lungu M, Danci AG, Sabau M, Strilciuc S, Popescu BO (2024) Levodopa-Carbidopa-Entacapone intestinal gel in advanced Parkinson disease: a multicenter real-life experience. Am J Ther. https:\/\/doi.org\/10.1097\/MJT.0000000000001707","journal-title":"Am J Ther"},{"key":"3182_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040453","author":"S Szatmari","year":"2024","unstructured":"Szatmari S, Szasz JA, Orban-Kis K, Baroti B, Bataga S, Ciorba M, Nagy EE, Neagoe RM, Mihaly I, Szasz PZ, Kelemen K, Frigy A, Szilveszter M, Constantin VA (2024) Levodopa-entacapone-carbidopa intestinal gel in the treatment of advanced parkinson\u2019s disease: a single center real-world experience. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics16040453","journal-title":"Pharmaceutics"},{"issue":"4","key":"3182_CR43","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F, Frauscher B, Hulsmann J, Martinez-Martin P, Chaudhuri KR (2011) Parkinson\u2019s disease sleep scale\u2013validation of the revised version PDSS-2. Mov Disord 26(4):644\u2013652. https:\/\/doi.org\/10.1002\/mds.23476","journal-title":"Mov Disord"},{"issue":"s1","key":"3182_CR44","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-181476","volume":"8","author":"DJ van Wamelen","year":"2018","unstructured":"van Wamelen DJ, Grigoriou S, Chaudhuri KR, Odin P (2018) Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson\u2019s Disease. J Parkinson\u2019s disease 8(s1):S65\u2013S72. https:\/\/doi.org\/10.3233\/JPD-181476","journal-title":"J Parkinson\u2019s disease"},{"issue":"1","key":"3182_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ane.13336","volume":"143","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen DJ, Martinez-Martin P, Weintraub D, Schrag A, Antonini A, Falup-Pecurariu C, Odin P, Ray Chaudhuri K, International P, Movement Disorder Society Parkinson\u2019s Disease Non-Motor Study G (2021) The Non-Motor Symptoms Scale in Parkinson\u2019s disease: Validation and use. Acta Neurol Scand 143(1):3\u201312. https:\/\/doi.org\/10.1111\/ane.13336","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"3182_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/mdc3.13926","volume":"11","author":"V Viljaharju","year":"2024","unstructured":"Viljaharju V, Mertsalmi T, Pauls KAM, Koivu M, Eerola-Rautio J, Udd M, Pekkonen E (2024) Levodopa-Entacapone-Carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease: a single-center study of 30 patients. Mov Disord Clin Pract 11(2):159\u2013165. https:\/\/doi.org\/10.1002\/mdc3.13926","journal-title":"Mov Disord Clin Pract"},{"key":"3182_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-03033-8","author":"T Warnecke","year":"2025","unstructured":"Warnecke T, Odin P, Garcia-Ramos R, Lopez L, Tulba D, Dan TF, Jianu DC, Rozankovic PB, van Laar T (2025) Effects of levodopa-entacapone-carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson\u2019s disease-interim analysis of the ELEGANCE study. J Neural Transm (Vienna). https:\/\/doi.org\/10.1007\/s00702-025-03033-8","journal-title":"J Neural Transm (Vienna)"},{"key":"3182_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70046","author":"D Weiss","year":"2025","unstructured":"Weiss D, Jost WH, Szasz JA, Pirtosek Z, Milanov I, Tomantschger V, Kovacs N, Staines H, Amlani B, Smith N, van Laar T (2025) Levodopa-Entacapone-Carbidopa intrajejunal infusion in advanced Parkinson\u2019s disease - interim analysis of the ELEGANCE study. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70046","journal-title":"Mov Disord Clin Pract"},{"issue":"7","key":"3182_CR49","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3233\/JPD-240181","volume":"14","author":"SY Yoon","year":"2024","unstructured":"Yoon SY, Choi JY, Nam GE, Jung JH, Han K, Kang SH, Kim CK, Kim YW, Koh SB (2024) Association between Body Mass Index changes and all-cause mortality in Parkinson\u2019s disease. J Parkinsons Dis 14(7):1441\u20131450. https:\/\/doi.org\/10.3233\/JPD-240181","journal-title":"J Parkinsons Dis"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03182-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03182-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03182-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:59:54Z","timestamp":1780063194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03182-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":49,"alternative-id":["3182"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03182-4","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ELEGANCE study enrolled patients admitted to the Neurological Clinics of University Teaching Hospitals in Romania to which the authors are affiliated. In accordance with national legislation and the Declaration of Helsinki, all patients had to sign the written consent form of the teaching hospital before enrolment in the ELEGANCE study. According to Romanian national legislation and institutional policies at the time of the study, non\u2011interventional observational studies based solely on data collected during routine clinical care and covered by the hospital\u2019s informed consent do not require separate approval from a research ethics committee; therefore, no additional ethics committee approval was sought. We confirm that all authors have read the Journal\u2019s guidelines on compliance with ethical standards and affirm that this work is consistent with those guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Financial disclosures related to this article: The ELEGANCE study is sponsored by Britannia Pharmaceuticals Ltd. Funding for statistical analysis of data and editorial assistance during manuscript development was provided by Britannia Pharmaceuticals Ltd. J\u00f3zsef Attila Sz\u00e1sz and Bogdan Ovidiu Popescu are paid by Britannia Pharmaceuticals Ltd. as members of the ELEGANCE study steering committee.Other competing interests: J\u00f3zsef Attila Sz\u00e1sz: Consultancy and speaking honoraria from AbbVie, Boehringer-Ingelheim, GSK, Lundbeck, Novartis, Pfizer, Stada, Teva, and UCB. Alina Vasilica Blesneag: Honoraria for speaker activities and scientific engagements from AbbVie, Ever Pharma, Organon, STADA, Teva, Terapia, and UCB.Dan Traian Flavius: Speaker\u2019s honoraria from AbbVie, Boehringer-Ingelheim, Stada, Organon, and Terapia.Viorelia Adelina Constantin: Speaker\u2019s honoraria from AbbVie, Bayer, UCB, W\u00f6rwag Pharma. Stada, and Pfizer.Dafin Fior Mure\u015fanu: No conflicts of interest to report.Drago\u015f C\u0103t\u0103lin Jianu: Speaker\u2019s honoraria from AbbVie, Stada, Boehringer-Ingelheim, Teva, and Organon.Any Axelerad: Speaker\u2019s honoraria from AbbVie, Boehringer-Ingelheim, GSK, Lundbeck, Novartis, Pfizer, Stada, Teva, UCB, W\u00f6rwag Pharma, Sanofi, Krka, Gedeon Richter, Eli Lilly, Zentiva, Takeda, Janssen,, Merck, Medison Pharma, Labormed Pharma, Roche, and Ipsen Pharma. Delia Tulb\u0103: Speaker\u2019s honoraria from AbbVie and Stada.Bogdan Ovidiu Popescu: Honoraria for advisory boards and educational lectures from Britannia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}